Abstract：Objective To observe the clinical effect and toxicity of Amlotinib in second-line treatment of advanced non-small cell lung cancer. Methods A total of 52 patients with advanced non-small cell lung cancer admitted to People′s Hospital of Chaozhou City from January 2019 to March 2020 were selected as the research objects. After progression of first-line chemotherapy, the patients were divided into chemotherapy group (32 cases) and Amlotinib group(20 cases) on a voluntary basis. Patients in the chemotherapy group were treated with Paclitaxel combined with Cisplatin, and patients in the Amlotinib group were treated with Amlotinib Capsules orally. The short-term efficacy and the occurrence of toxic and side effects were compared between the two groups. Results There were no statistically significant differences in objective effective rate and disease control rate between the two groups (P＞0.05). The incidence of anorexia and gastrointestinal reactions in the Amlotinib group were lower than those in the chemotherapy group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the incidence rates of bleeding, hypertension, myelosuppression, hand-foot syndrome, oral ulcer, liver and kidney function injury and fatigue between the two groups (P＞0.05). Conclusion The clinical effect of Amlotinib as a second-line regimen in advanced non-small cell patients is similar to that of chemotherapy , and the adverse reactions are fewer.
Chen AP，Setser A，Anadkat MJ，et al.Grading dermatologic adverse events of cancer treatments：the Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol，2012，67（5）：1025-1039.
[5]
Jayson GC，Kerbel R，Ellis LM，et al.Antiangiogenic therapy in oncology：current status and future directions[J].Lancet，2016，388（10043）：518-529.
Liu Z，Wang J，Meng Z，et al.P3.01-084 Analysis on ALTER0303 Trial：aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC[J].J Thorac Oncol，2017，12（11）：S2234-S2235.
[13]
Han B，Li K，Wang Q，et al.Effect of Anlotinib as a third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer：The ALTER0303 phase 3 randomized clinical trial[J].JAMA Oncol，2018，4（11）：1569-1575.
京公网安备 11010502046607号